These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 17289685

  • 1. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
    Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ.
    BMJ; 2007 Mar 31; 334(7595):674. PubMed ID: 17289685
    [Abstract] [Full Text] [Related]

  • 2. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F, Sanchez O, Pernod G, Mismetti P, Jego P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Guégan M, Bosson JL, Laporte S, Leroyer C, Décousus H, Meyer G, Mottier D, PADIS-PE Investigators.
    JAMA; 2015 Jul 07; 314(1):31-40. PubMed ID: 26151264
    [Abstract] [Full Text] [Related]

  • 3. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E.
    N Engl J Med; 1997 Feb 06; 336(6):393-8. PubMed ID: 9010144
    [Abstract] [Full Text] [Related]

  • 4. Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial.
    Couturaud F, Pernod G, Presles E, Duhamel E, Jego P, Provost K, Pan-Petesch B, Sollier CBD, Tromeur C, Hoffmann C, Bressollette L, Lorillon P, Girard P, Le Moigne E, Le Hir A, Guégan M, Laporte S, Mismetti P, Lacut K, Bosson JL, Bertoletti L, Sanchez O, Meyer G, Leroyer C, Mottier D, “PADIS-DVT” investigators.
    Haematologica; 2019 Jul 06; 104(7):1493-1501. PubMed ID: 30606789
    [Abstract] [Full Text] [Related]

  • 5. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May 06; 22(138):129-33. PubMed ID: 23819181
    [Abstract] [Full Text] [Related]

  • 6. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators.
    N Engl J Med; 2001 Jul 19; 345(3):165-9. PubMed ID: 11463010
    [Abstract] [Full Text] [Related]

  • 7. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG.
    Lancet Haematol; 2016 Jan 19; 3(1):e12-21. PubMed ID: 26765643
    [Abstract] [Full Text] [Related]

  • 8. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA.
    N Engl J Med; 1999 Mar 25; 340(12):901-7. PubMed ID: 10089183
    [Abstract] [Full Text] [Related]

  • 9. Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study.
    Vucić N, Ostojić R, Svircić T.
    Croat Med J; 2002 Jun 25; 43(3):296-300. PubMed ID: 12035135
    [Abstract] [Full Text] [Related]

  • 10. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.
    Lancet; 1992 Oct 10; 340(8824):873-6. PubMed ID: 1357297
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extended oral anticoagulant therapy after a first episode of pulmonary embolism.
    Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P, Warfarin Optimal Duration Italian Trial Investigators.
    Ann Intern Med; 2003 Jul 01; 139(1):19-25. PubMed ID: 12834314
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
    Tullett J, Murray E, Nichols L, Holder R, Lester W, Rose P, Hobbs FD, Fitzmaurice D.
    BMC Cardiovasc Disord; 2013 Mar 09; 13():16. PubMed ID: 23497371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.